At the American Association for Cancer Research meeting, April 2024 – we presented a poster titled “Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer.” 

We attended TRI-CON 2024. If you missed us, contact us to learn about Virtuoso, our epigenomic platform that provides an unprecedented level of clarity to inform cancer diagnosis and treatment. Or, get more information on our presentation! Epigenomic Tools for Early...

European Neuroendocrine Tumor Society, March 2024 – Oral presentation entitled “ 5-Hydroxymethylcytosine profiling of plasma-derived circulating free DNA in patients with pancreatic neuroendocrine tumors treated with [177Lu]Lu-DOTA-TATE.” 

Circulating Nucleic Acids in Plasma Symposium, March 2024 – Oral presentation entitled “Plasma cell-free DNA hydroxymethylation profiling reveals anti-PD1 treatment response and resistance biology in non-small cell lung cancer.” 

PRECEDE – The Pancreatic Cancer Early Detection Consortium, December 6th, and 7th , 2023 

American Pancreatic Association, December 2023 – Poster presentation “SAFE-D Trial design: Targeted pancreatic cancer screening to evaluate stage and resectability rate shift in patients with new-onset diabetes.”

American Diabetes Association 83rd Scientific Sessions, June 2023 - Poster presentation entitled “Implementation of the Avantect Pancreatic Cancer Test in Newly Diagnosed Type 2 Diabetes Patients in a Clinical Setting.” Meet Us At ADA Booth #1814 ClearNote Health is a...

Society for Laboratory Automation and Screening, May 2023 – Oral presentation “Automation of an Early Detection Pancreatic Cancer Test Using 5-Hydroxymethylation Profiles.”   

American Association for Cancer Research, April 2023 – Poster presentation “Evaluation of the Avantect Pancreatic Cancer Test for Identifying High-Risk Pancreatic Cysts.” 

American Society of Clinical Oncology, Gastrointestinal, January 2023 – Poster presentation “Early detection of pancreatic cancer using 5-hydroxymethylation profiles in plasma-derived cell-free DNA.”